ASPI CEO Targets $300M EBITDA by 2031, but Near-Term Proof Still Missing

What happened

ASP Isotopes CEO Paul Mann outlined plans to expand isotope-enrichment, radiopharmacy, and helium businesses, targeting more than $300 million in EBITDA by 2031. The announcement comes as the company still reports zero revenue from enriched isotopes as of Q1 2026, despite targets for initial commercial shipments of Si-28, C-14, and Yb-176 in 2026. The DeepValue master report rates ASPI WAIT with a base case of $6.50, highlighting the gap between production claims and monetization. The new long-term EBITDA goal does not address the near-term catalysts of first isotope sales, TerraPower loan drawdowns, or Renergen nameplate achievement. Investors should view this as an aspirational update that increases focus on execution but does not change the current valuation picture.

Implication

The 2031 EBITDA target provides a multi-year north star, but it is contingent on successful execution across all segments, requiring significant capital and operational milestones. If achieved, $300M EBITDA could justify a substantially higher valuation, but the path is fraught with dilution risk from funding the $1.16B Renergen Phase 2 and HALEU buildout. The master report's base case of $6.50 and bear case of $3.25 remain valid absent concrete near-term catalysts. Investors should monitor quarterly filings for recognized isotope product revenue and TerraPower loan drawdowns, as those will validate the long-term goal. Until then, the stock is likely to remain range-bound between $4.75 and $7.25.

Thesis delta

The news reinforces the long-term growth narrative but does not alter the near-term thesis that ASPI must convert production into recognized isotope revenue. The $300M EBITDA target by 2031 is aspirational and provides no incremental evidence of 2026 shipment execution or customer acceptance. Therefore, the thesis remains unchanged: WAIT until at least one quarter shows isotope sales revenue.